MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Orchestra BioMed Holdings, Inc. - Ordinary Shares (NQ:OBIO)

2.680 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,367
Open 2.680
Bid (Size) 2.610 (1)
Ask (Size) 2.700 (2)
Prev. Close 2.680
Today's Range 2.680 - 2.680
52wk Range 2.200 - 6.500
Shares Outstanding 38,194,442
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga

Performance

YTD
-50.2%
-50.2%
1 Month
-2.2%
-2.2%
3 Month
-7.3%
-7.3%
6 Month
-13.8%
-13.8%
1 Year
-45.7%
-45.7%

More News

Read More
Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
This Applied Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Orchestra BioMed Announces Pricing of $40 Million Public Offering
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
These stocks are moving in today's after hours session
Via Chartmill
Orchestra BioMed Announces Proposed Public Offering
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Sidoti Events, LLC's Virtual May Micro-Cap Conference
Via ACCESS Newswire
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
SmallCaps Gaining Momentum: TIVC, GELS, SLI, OBIO in Healthcare, Biotech, Energy, Military Defense, Etc. – More Stocks Inside
Via AB Newswire
Topics Government
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Orchestra BioMed Holdings, Inc. - Ordinary Shares publicly traded?
Yes, Orchestra BioMed Holdings, Inc. - Ordinary Shares is publicly traded.
What exchange does Orchestra BioMed Holdings, Inc. - Ordinary Shares trade on?
Orchestra BioMed Holdings, Inc. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Orchestra BioMed Holdings, Inc. - Ordinary Shares?
The ticker symbol for Orchestra BioMed Holdings, Inc. - Ordinary Shares is OBIO on the Nasdaq Stock Market
What is the current price of Orchestra BioMed Holdings, Inc. - Ordinary Shares?
The current price of Orchestra BioMed Holdings, Inc. - Ordinary Shares is 2.680
When was Orchestra BioMed Holdings, Inc. - Ordinary Shares last traded?
The last trade of Orchestra BioMed Holdings, Inc. - Ordinary Shares was at 10/02/25 04:00 PM ET
What is the market capitalization of Orchestra BioMed Holdings, Inc. - Ordinary Shares?
The market capitalization of Orchestra BioMed Holdings, Inc. - Ordinary Shares is 102.36M
How many shares of Orchestra BioMed Holdings, Inc. - Ordinary Shares are outstanding?
Orchestra BioMed Holdings, Inc. - Ordinary Shares has 102M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story